The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•23 March 2026•

1 min read

Trinity Biotech Announces Successful Clinical Results for Enhanced Prostate Cancer Test

A world map in golden tones with overlaid financial charts showing a downward trend, a large blue arrow pointing down, and falling circuit boards and text. Two screens display NASDAQ data.

Key Facts

1Trinity Biotech (TRIB) announced successful clinical study results for an enhanced version of its EpiCapture™ prostate cancer test.

Trinity Biotech plc (Nasdaq: TRIB) has announced successful clinical study results for an enhanced version of its EpiCapture™ prostate cancer test. The diagnostic tool is specifically engineered to provide higher precision in predicting the risk of aggressive prostate cancer compared to previous versions. This milestone follows a rigorous validation process aimed at improving the effectiveness of the diagnostic tool for broader market adoption. These positive outcomes represent a significant advancement for the company's oncology portfolio and its diagnostic capabilities. Investors are likely to view this data as a strong indicator of potential future commercial success and regulatory progress. Furthermore, the enhanced test aims to reduce unnecessary medical procedures by accurately identifying patients who require urgent intervention.